-
Tytuł:
-
Potential human transmission of amyloid β pathology: surveillance and risks.
-
Autorzy:
-
Lauwers E; VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Lalli G; UK Dementia Research Institute, University College London, London, UK.
Brandner S; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London National Health Service Foundation Trust, London, UK.
Collinge J; Medical Research Council Prion Unit at UCL, Institute of Prion Diseases, University College London, London, UK.
Compernolle V; Blood Services, Belgian Red Cross-Flanders, Mechelen, Belgium; Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Duyckaerts C; Institut du Cerveau et de la Moelle épinière, Sorbonne University, INSERM, CNRS UMR, Paris, France; Laboratoire de Neuropathologie Raymond Escourolle, Hôpital de la Pitié-Salpêtrière, Assistance Publique- Hôpitaux de Paris, Paris, France.
Edgren G; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Södersjukhuset, Stockholm, Sweden.
Haïk S; Institut du Cerveau et de la Moelle épinière, Sorbonne University, INSERM, CNRS UMR, Paris, France; Laboratoire de Neuropathologie Raymond Escourolle, Hôpital de la Pitié-Salpêtrière, Assistance Publique- Hôpitaux de Paris, Paris, France; Cellule Nationale de Référence des maladies de Creutzfeldt-Jakob, Hôpital de la Pitié-Salpêtrière, Assistance Publique- Hôpitaux de Paris, Paris, France.
Hardy J; UK Dementia Research Institute, University College London, London, UK; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK; Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong Special Administrative Region, China.
Helmy A; Department of Clinical Neuroscience, Division of Neurosurgery, University of Cambridge, Cambridge, UK.
Ivinson AJ; UK Dementia Research Institute, University College London, London, UK.
Jaunmuktane Z; Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK; Queen Square Brain Bank for Neurological Disorders, Queen Square Institute of Neurology, University College London, London, UK; Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London National Health Service Foundation Trust, London, UK.
Jucker M; Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases, Tübingen, Germany.
Knight R; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK; National Creutzfeldt-Jakob Disease Research and Surveillance Unit, Western General Hospital, Edinburgh, UK.
Lemmens R; VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium; Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Lin IC; UK Dementia Research Institute, University College London, London, UK.
Love S; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Mead S; Medical Research Council Prion Unit at UCL, Institute of Prion Diseases, University College London, London, UK.
Perry VH; UK Dementia Research Institute, University College London, London, UK.
Pickett J; Alzheimer's Society, London, London, UK; Epilepsy Research UK, London, UK.
Poppy G; Biological Sciences, University of Southampton, Southampton, UK.
Radford SE; Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK.
Rousseau F; VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Routledge C; Alzheimer's Research UK, Cambridge, UK.
Schiavo G; UK Dementia Research Institute, University College London, London, UK; Department of Neuromuscular Disorders, UCL Queen Square Institute of Neurology, University College London, London, UK.
Schymkowitz J; VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Selkoe DJ; Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Harvard University, Boston, MA, USA.
Smith C; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Thal DR; Department of Imaging and Pathology, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
Theys T; Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.
Tiberghien P; Etablissement Français du Sang, La Plaine St Denis, France; Unité Mixte de Recherche, INSERM, Université de Franche-Comté, Besançon, France.
van den Burg P; European Blood Alliance, Brussels, Belgium; Department of Transfusion Medicine, Sanquin, Amsterdam, Netherlands.
Vandekerckhove P; Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Blood Services, Belgian Red Cross-Flanders, Mechelen, Belgium.
Walton C; Alzheimer's Society, London, London, UK; Multiple Sclerosis International Federation, London, UK.
Zaaijer HL; Department of Blood-borne Infections, Sanquin, Amsterdam, Netherlands.
Zetterberg H; UK Dementia Research Institute, University College London, London, UK; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK; Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
De Strooper B; VIB-KU Leuven Center for Brain and Disease Research, KU Leuven, Leuven, Belgium; Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium; UK Dementia Research Institute, University College London, London, UK. Electronic address: .
-
Źródło:
-
The Lancet. Neurology [Lancet Neurol] 2020 Oct; Vol. 19 (10), pp. 872-878. Date of Electronic Publication: 2020 Sep 16.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: London, UK ; New York, NY : Lancet Pub. Group, 2002-
-
MeSH Terms:
-
Population Surveillance*
Amyloid beta-Peptides/*metabolism
Neurodegenerative Diseases/*metabolism
Alzheimer Disease/etiology ; Alzheimer Disease/metabolism ; Alzheimer Disease/pathology ; Amyloid beta-Peptides/toxicity ; Animals ; Creutzfeldt-Jakob Syndrome/metabolism ; Creutzfeldt-Jakob Syndrome/pathology ; Creutzfeldt-Jakob Syndrome/transmission ; Humans ; Neurodegenerative Diseases/etiology ; Neurodegenerative Diseases/pathology ; Parkinson Disease/etiology ; Parkinson Disease/metabolism ; Parkinson Disease/pathology ; Risk Factors
-
Grant Information:
-
MC_U123160651 United Kingdom MRC_ Medical Research Council; MC_UU_00024/9 United Kingdom MRC_ Medical Research Council; MR/L501542/1 United Kingdom MRC_ Medical Research Council; MC_UP_1604/1 United Kingdom MRC_ Medical Research Council; MR/N026004/1 United Kingdom MRC_ Medical Research Council; G0802251 United Kingdom MRC_ Medical Research Council; MR/L016400/1 United Kingdom MRC_ Medical Research Council; G0701075 United Kingdom MRC_ Medical Research Council; G0901254 United Kingdom MRC_ Medical Research Council; MC_UU_00024/1 United Kingdom MRC_ Medical Research Council; G-0907 United Kingdom PUK_ Parkinson's UK; MC_U123160657 United Kingdom MRC_ Medical Research Council; G0400713 United Kingdom MRC_ Medical Research Council
-
Substance Nomenclature:
-
0 (Amyloid beta-Peptides)
-
Entry Date(s):
-
Date Created: 20200919 Date Completed: 20200930 Latest Revision: 20240306
-
Update Code:
-
20240306
-
DOI:
-
10.1016/S1474-4422(20)30238-6
-
PMID:
-
32949547
-
Studies in experimental animals show transmissibility of amyloidogenic proteins associated with prion diseases, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. Although these data raise potential concerns for public health, convincing evidence for human iatrogenic transmission only exists for prions and amyloid β after systemic injections of contaminated growth hormone extracts or dura mater grafts derived from cadavers. Even though these procedures are now obsolete, some reports raise the possibility of iatrogenic transmission of amyloid β through putatively contaminated neurosurgical equipment. Iatrogenic transmission of amyloid β might lead to amyloid deposition in the brain parenchyma and blood vessel walls, potentially resulting in cerebral amyloid angiopathy after several decades. Cerebral amyloid angiopathy can cause life-threatening brain haemorrhages; yet, there is no proof that the transmission of amyloid β can also lead to Alzheimer's dementia. Large, long-term epidemiological studies and sensitive, cost-efficient tools to detect amyloid are needed to better understand any potential routes of amyloid β transmission and to clarify whether other similar proteopathic seeds, such as tau or α-synuclein, can also be transferred iatrogenically.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Comment in: Lancet Neurol. 2020 Oct;19(10):802-803. (PMID: 32949533)
Erratum in: Lancet Neurol. 2020 Nov;19(11):e10. (PMID: 33098805)
